ASBP vs ATHE

Aspire Biopharma Holdings, Inc. vs Alterity Therapeutics Limited — Valuation Comparison 2026

ASBP

Biotechnology
Aspire Biopharma Holdings, Inc.
Quality
4.6
out of 10
Value Trap
22
SAFE
Price
$5.53
Last close
Models
8/13
Active
VS

ATHE

Biotechnology
Alterity Therapeutics Limited
Quality
1.8
out of 10
Value Trap
Price
$4.08
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ASBP Fair ValueASBP Upside ATHE Fair ValueATHE Upside
Bayesian DCF Intrinsic $3.92 -29.0% $1.08 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.07 -73.5%
PWERM Option-Based $7.61 +37.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ASBP vs ATHE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ASBP vs ATHE — Which Stock Is More Undervalued?

ASBP scores higher with a 4.6/10 quality rating vs ATHE's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aspire Biopharma Holdings, Inc. (ASBP) and Alterity Therapeutics Limited (ATHE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ASBP currently trades at $5.53 with a QOC of 4.6/10, while ATHE trades at $4.08 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).